All Search Results
News Releases
Apr 08, 2026, 09:00 ET Courier Health Releases 2026 State of Patient-Centricity in Biopharma Report
Download the full report for more insights, including interviews with executives from AstraZeneca, Denali Therapeutics, Genentech, Pfizer, and UCB.MethodologyThis survey was conducted online from January 13, 2026, to February 3, 2026. It included
More news about: Courier Health
Mar 31, 2026, 20:49 ET The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
a landmark approval, but it also highlights the manufacturing complexity: each treatment is custom-made from the patient's own tumor tissue. Denali Therapeutics (NASDAQ: DNLI) is advancing tividenofusp alfa for Hunter syndrome, with a PDUFA target date of April 2026 and Fast Track, Breakthrough Therapy,
More news about: USA News Group
Mar 24, 2026, 10:00 ET Advanced Cell-based Therapy Booming the Success for Healthcare Sector
custom-manufactured from the individual patient's own tumor tissue — underscoring how critical scalable cellular infrastructure is to the future of the field. Denali Therapeutics (NASDAQ: DNLI) is advancing tividenofusp alfa for Hunter syndrome, with a PDUFA target date of April 2026 and multiple FDA designations, requiring
More news about: USA News Group
Jan 09, 2026, 08:00 ET Press Registration Is Now Open for the 2026 ACMG Annual Clinical Genetics Meeting
Evening Corporate Educational Satellite SymposiaIn addition to the scientific program, several leading companies—including BioMarin, Denali Therapeutics, Oxford Nanopore Technologies, Sanofi, Sarepta Therapeutics, and others—will host satellite symposia featuring new developments and emerging
More news about: American College of Medical Genetics and Genomics
Nov 06, 2025, 16:05 ET Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth
across neurology, rare diseases, immunology, and other areas. Most recently, she served as chief medical officer and head of development at Denali Therapeutics, where she built and led the company's translational medicine and clinical development strategy. Adrienne
More news about: Eli Lilly and Company
